00853 MICROPORT
- 7.020
- -0.020-0.28%
MICROPORT News
(Tama: For Minimally Invasive Healthcare 00853) The target price for the “Synchronize with the Market” rating was raised to HK$9
Nomura Adjusts MicroPort Scientific's Price Target to HK$6.71 From HK$7.19, Keeps at Neutral
Nomura: Target price for Minimally Invasive Medicine (00853.HK) “neutral” rating reduced to HK$6.71
Minimally Invasive Healthcare (00853.HK): Implementation of the debt problem suggests focusing on subsequent loss reduction and payment
Minimally Invasive Healthcare (0853.HK) 2023 Performance Forecast Comment: Loss margin widens, performance forecast falls short of expectations
Nomura Adjusts MicroPort Scientific's Price Target to HK$7.19 From HK$17.59, Keeps at Neutral
CICC: Maintaining the Minimally Invasive Healthcare (00853) “Outperform the Industry” Rating Target Price Reduced to HK$10.6
Minimally Invasive Healthcare (00853.HK): 2023 performance forecast falls short of expectations and waits for convertible bonds to be implemented
Research Report Nuggets | CICC: Maintaining the “Outperforming Industry” Rating for Minimally Invasive Medicine and Lowers Target Price to HK$21
Minimally Invasive Healthcare (0853.HK) 2023 Semi-Annual Results Review: Fee Cuts Proceed Smoothly, Losses Narrow Year Over Year
Bank Rating | Credit Suisse: Lowering the target price of minimally invasive medicine to HK$18.5 and upgrading the rating to “outperform the market”
Minimally Invasive Medicine (00853.HK): In line with expectations in the first half of the year, cost reduction and efficiency continued to advance
Minimally Invasive Medicine (00853.HK): Revenue Accelerates and Losses Narrow
Nomura: Maintaining Minimally Invasive Medicine (00853)'s “Neutral” Rating Target Price Reduced to HK$17.95
Nomura Adjusts Microport's Price Target to HK$17.59 From HK$23.24, Keeps at Neutral
Big Bank Ratings | Credit Suisse: Lowers Target Price of Minimally Invasive Healthcare (0853.HK) to HK$20.5 “Neutral”
Credit Suisse: Maintaining Minimally Invasive Healthcare (00853) “Neutral” Rating Target Price Lowered to HK$20.5
Minimally invasive medicine (0853.HK): Costs drag down short-term performance and are expected to improve in 2023
Minimally invasive medicine (00853.HK): Overseas markets accelerate the release of core products
Minimally Invasive Medicine (00853.HK): The value of leading configurations of performance stress relief devices is showing
Analysis
Price Target
No Data
